Cosentyx Drug Market Report Scope & Overview:

The Cosentyx Drug Market was valued at USD 5.65 Billion in 2025 and is expected to reach USD 11.97 Billion by 2035, growing at a CAGR of 7.80% from 2026-2035.

The Cosentyx Drug Market tracks secukinumab, Novartis' interleukin-17A inhibitor prescribed across plaque psoriasis, psoriatic arthritis, ankylosing spondylitis and related inflammatory conditions, together with the originator's expanding set of biosimilar challengers. Growth remains anchored in an established prescriber base and a broad label, even as the competitive landscape shifts toward IL-17 and IL-23 class rivals and toward secukinumab biosimilars working through regulatory filings in multiple jurisdictions. Specialty and hospital-linked distribution channels continue to carry the bulk of dispensing volume, while online and retail-adjacent specialty pharmacy models expand fastest as payers push patients toward lower-cost fulfillment paths. Asia Pacific is emerging as the most active biosimilar filing region, reshaping competitive positioning well ahead of any single market's patent cliff.

⮞In 2025, Novartis reported that its Phase III GCAptAIN study of Cosentyx in giant cell arteritis did not meet its primary endpoint of sustained remission at week 52, though the drug showed numerically favorable results on cumulative steroid exposure versus placebo. The result illustrates how Cosentyx's commercial trajectory increasingly depends on label-expansion attempts beyond its core dermatology and rheumatology indications, even as its established business continues to perform across approved uses.

U.S. Cosentyx Drug Market Outlook

The U.S. Cosentyx Drug Market was valued at USD 2.23 Billion in 2025 and is expected to reach USD 4.55 Billion by 2035, growing at a CAGR of 7.40% from 2026-2035.

The U.S. Cosentyx Drug Market remains the largest single national market, supported by broad payer coverage, an established prescriber base across dermatology and rheumatology, and a label that already spans most major indications secukinumab competes in. Growth here trails the fastest-expanding regions because most eligible patients already have access to an IL-17 or IL-23 inhibitor, shifting the growth story toward switching, label depth and biosimilar entry timing rather than first-time biologic adoption. Regulatory activity among competing oral and injectable therapies continues to reshape prescribing patterns even where Cosentyx itself retains a strong position. Specialty pharmacy channels dominate U.S. dispensing, and payers are increasingly steering volume toward whichever IL-17 or IL-23 option clears utilization management fastest.

⮞In March 2026, Bristol Myers Squibb received U.S. Food and Drug Administration approval for Sotyktu in active psoriatic arthritis, the first selective TYK2 inhibitor authorized in the country specifically for that indication. The approval gives prescribers an oral alternative for a population that previously had limited options beyond injectable biologics such as Cosentyx, intensifying competition for new psoriatic arthritis starts in the U.S. market.

By Indication, Plaque Psoriasis Dominates the Cosentyx Drug Market and Psoriatic Arthritis Grows Fastest

Plaque psoriasis accounts for the largest indication share because it was secukinumab's original approved use and remains the indication with the deepest prescriber familiarity, the longest real-world safety record and the broadest payer coverage of any use on the label. Dermatologists treating moderate to severe disease continue to default to an established IL-17 inhibitor like Cosentyx before considering a newer or less-studied alternative, reinforcing the indication's lead even as competing therapies target the same patient population more aggressively each year across nearly every major prescribing market.

Psoriatic arthritis is growing fastest as rheumatologists increasingly start biologic therapy earlier in the disease course rather than waiting for conventional therapy to fail outright across multiple treatment cycles that can otherwise delay effective relief. Head-to-head trial data among competing IL-17 and IL-23 inhibitors has intensified competitive pressure specifically in this indication, pushing originator and rival manufacturers alike to generate fresh comparative evidence to defend or gain psoriatic arthritis prescribing share across the broader rheumatology prescriber base treating this growing patient population.

⮞In September 2025, Johnson & Johnson's Tremfya received U.S. Food and Drug Administration approval for pediatric plaque psoriasis and active psoriatic arthritis, marking the first approval of an IL-23 inhibitor for pediatric patients in either indication. The approval extends IL-23 class competition into a younger patient population that Cosentyx has historically served primarily through its adult label.

By Route of Administration, Subcutaneous Dominates the Cosentyx Drug Market and Others Grows Fastest

Subcutaneous administration accounts for the largest route-of-administration share because it lets patients self-inject at home after an initial training period, avoiding the cost and scheduling burden of infusion-center visits that intravenous biologics typically require. Cosentyx and nearly every competing IL-17 or IL-23 inhibitor on the market are formulated primarily for subcutaneous delivery, making this the default route patients and prescribers expect from the entire drug class covered in this market, reinforcing patient familiarity with self-administration across treatment years. Manufacturers continue investing in autoinjector refinements specifically because this route carries most of the category's prescribing volume.

The Others category, covering newer single-injection and higher-concentration device formats, is growing fastest as manufacturers compete on convenience rather than efficacy alone once a drug's core safety and effectiveness profile is well established. Reducing the number of injections needed per dose has become a meaningful differentiator in a therapeutic class where multiple products otherwise treat overlapping patient populations with broadly similar outcomes, giving device design an outsized role in prescribing decisions. Patients managing a chronic condition over many years notice and often prefer these incremental convenience gains.

⮞In January 2025, UCB made its Bimzelx 320 mg single-injection device, delivered as one 2 mL injection rather than two separate 1 mL injections, available to patients across its approved indications. The device-level change illustrates how administration convenience is becoming a competitive battleground among IL-17 and IL-23 inhibitors that increasingly compete on patient experience rather than purely on clinical data.

By Distribution Channel, Hospital Pharmacies Dominate the Cosentyx Drug Market and Online Pharmacies Grow Fastest

Hospital pharmacies account for the largest distribution-channel share because many patients are first prescribed Cosentyx during a dermatology or rheumatology hospital visit, and hospital-affiliated specialty pharmacies are often best equipped to manage the prior-authorization and benefits-verification steps a biologic like this requires. This channel also tends to retain patients through refill cycles once a hospital system's specialty pharmacy has already handled the complex onboarding process for a given patient, giving it a durable advantage over channels that only see a patient occasionally.

Online pharmacies are growing fastest as payers and pharmacy benefit managers direct more specialty biologic fulfillment toward centralized mail-order and digital-first dispensing models that can process prior authorizations and insurance steps more efficiently than a traditional storefront. Patients managing a chronic condition over many years increasingly prefer the convenience of scheduled home delivery over repeat pharmacy visits for a drug they already know how to self-administer, a preference payers are actively encouraging through channel-specific cost structures that steer volume accordingly.

⮞In February 2025, Teva and Alvotech began U.S. commercialization of Selarsdi, a biosimilar competing in the same broader specialty-biologic distribution ecosystem that Cosentyx dispensing relies on, following a legal settlement that had delayed its originally planned launch date. The launch reflects how specialty distribution channels are increasingly built to handle a growing roster of competing biologic and biosimilar products at once.

By Product Type, Originator Brand Dominates the Cosentyx Drug Market and Biosimilars Grows Fastest

The originator brand accounts for the overwhelming majority of product-type share because no secukinumab biosimilar has yet reached full commercial approval in a major market, leaving Novartis as the sole current supplier of the molecule itself despite a growing field of biosimilar developers working through clinical and regulatory stages. This near-exclusive position has let Novartis defend pricing and contracting terms that a biosimilar entrant would typically erode once available, though that advantage is visibly narrowing as filings accumulate.

Biosimilars are growing fastest, from a small base, as multiple developers advance secukinumab candidates through parallel regulatory filings across different jurisdictions rather than concentrating effort on a single market first. The sheer number of distinct biosimilar programs now active suggests that once the first approval lands, a wave of near-simultaneous launches across several regions could follow rather than a single gradual rollout, compressing the originator's exclusivity window more significantly than in prior biosimilar launches.

⮞In July 2026, Celltrion submitted a Marketing Authorization Application to the European Medicines Agency for CT-P55, its secukinumab biosimilar, after earlier filings in Canada in May 2026 and South Korea in June 2026, with the EU application seeking approval across all of Cosentyx's European indications. The filing sequence shows a biosimilar developer deliberately building regulatory momentum across several jurisdictions before any single approval has even landed.

Regional Analysis

North America Cosentyx Drug Market Insights

With a share of 45.80% in 2025, North America led the market, supported by the deepest prescriber base for IL-17 and IL-23 inhibitors anywhere in the world and payer coverage structures that already accommodate Cosentyx across most of its approved indications. Canada contributes a smaller, steady share shaped by its own public reimbursement pathways for specialty biologics, following many of the same prescribing patterns seen more broadly across the North American market as a whole.

The region's lead reflects years of accumulated prescribing experience and brand loyalty built before most current competitors reached the market, even though growth here now trails faster-expanding regions where biologic adoption is still climbing from a lower base. Competing therapies from AbbVie, Johnson & Johnson and Bristol Myers Squibb are each fighting for a larger share of new patient starts within this already-mature prescriber base, keeping competitive intensity unusually high for a region this far along its own adoption curve and overall prescribing maturity today.

⮞In the second quarter of 2026, AbbVie reported Skyrizi sales of USD 5.55 billion, up 24% year over year, and raised its 2026 revenue projection for the product, underscoring how intensely IL-23 inhibitors are competing for the same North American psoriasis and psoriatic arthritis patients that Cosentyx has long served.

Asia Pacific Cosentyx Drug Market Insights

Asia Pacific is the fastest-growing region, projected to expand at a CAGR of 8.60% from 2026 to 2035, as rising diagnosis rates for psoriasis and psoriatic arthritis combine with an unusually active local biosimilar manufacturing base pursuing secukinumab candidates. Regulatory agencies across the region's largest markets have been accepting biosimilar filings at a pace that suggests near-term approvals rather than a distant, multi-year horizon, a sharp contrast with how slowly comparable biosimilar transitions have historically unfolded in other regions.

Growth here is pulled by both rising biologic adoption among patients newly diagnosed with inflammatory disease and the region's extensive secukinumab biosimilar pipeline, which includes several distinct Chinese developers advancing candidates in parallel. This combination gives the region a broader, more diversified set of growth drivers than markets where originator Cosentyx faces little direct biosimilar competition yet, positioning Asia Pacific as the region where secukinumab biosimilar competition is likely to be tested first and most visibly over the coming years.

⮞In June 2026, CSPC Pharmaceutical Group announced that China's National Medical Products Administration had accepted its marketing authorization application for a secukinumab biosimilar, covering the same plaque psoriasis, psoriatic arthritis and ankylosing spondylitis indications Cosentyx holds in China. The filing adds a major Chinese manufacturer to an already competitive regional biosimilar field.

Europe Cosentyx Drug Market Insights

Europe holds a share behind North America and Asia Pacific, with Germany hosting the region's largest concentration of dermatology and rheumatology biologic prescribing tied to its large, centrally reimbursed specialty-pharmaceutical market. The United Kingdom, France, Italy, Spain, Poland and Russia each contribute smaller but steady amounts of regional demand as national health systems continue funding biologic therapy for eligible inflammatory-disease patients across their respective reimbursement frameworks, which vary meaningfully in how quickly a given new therapy reaches funded status for patients.

European regulators have become an early battleground for secukinumab biosimilar approval given the EMA's centralized filing pathway, meaning the first biosimilar competition Cosentyx faces in a major market could plausibly originate from a European filing rather than a national one elsewhere. This regulatory structure gives the region outsized influence over how quickly biosimilar competition actually reaches patients once a filing is accepted, since one EMA decision can open multiple national markets simultaneously rather than requiring separate country-by-country review each time.

⮞In July 2026, Celltrion submitted its Marketing Authorization Application for CT-P55 to the European Medicines Agency, seeking approval across every indication Cosentyx already holds in the region, after filing first in Canada and South Korea earlier the same year. The EU filing is widely viewed as the pivotal step toward the region's first approved secukinumab biosimilar.

MEA & Latin America Cosentyx Drug Market Insights

The Middle East and Africa remains a small but growing market, with South Africa hosting the region's most established dermatology and rheumatology biologic prescribing base while the United Arab Emirates and Saudi Arabia expand specialty-pharmaceutical access as part of broader healthcare investment programs. Biosimilar competition has not meaningfully reached the region yet, so most prescribing still runs through the originator brand and its existing distribution relationships rather than through a regionally commercialized alternative, leaving pricing largely unchanged for now.

Latin America contributes a modest share, led by Brazil, where public and private payers are gradually expanding biologic therapy access for psoriasis and psoriatic arthritis patients alongside broader investment in specialty-care infrastructure. Argentina, Mexico and Colombia add smaller but growing demand as reimbursement pathways mature across the region. Global biosimilar developers building out commercialization partnerships across multiple regions are expected to eventually extend coverage into Latin America once their lead markets are secured, following the same sequencing pattern seen in other biosimilar categories already established there.

⮞In March 2026, Samsung Bioepis and Sandoz expanded their biosimilar partnership to cover up to five next-generation candidates, with Sandoz handling commercialization across global markets outside a short list of excluded territories. Partnership structures of this kind are how large biosimilar portfolios typically reach the Middle East, Africa and Latin America, even though the specific candidates named in this agreement target other reference biologics rather than secukinumab directly.

Market Dynamics

Growth Drivers: An extensive biosimilar pipeline is accelerating the pace of competitive entry into the secukinumab market

The strongest driver is the unusually large number of secukinumab biosimilar programs advancing through clinical and regulatory stages at once, a pipeline density that increases the odds of near-simultaneous approvals across several major markets rather than one slow, staggered rollout. This concentration of developer interest signals strong confidence in the underlying commercial opportunity secukinumab still represents even as its original patent protection winds down across its largest markets over the next several years of this entire forecast period.

A second driver is continued label-expansion activity by the originator and by competing IL-17 and IL-23 inhibitors alike, which keeps total addressable patient volume growing even as individual products compete more directly for the same prescribing decisions. New indications and earlier-line use both expand the number of patients eligible for a biologic in this class before biosimilar price competition even becomes a meaningful factor in how physicians and payers choose between the growing roster of available treatment options available to them today.

⮞In July 2025, Sun Pharmaceutical Industries announced that the FDA had accepted its supplemental Biologics License Application seeking approval of Ilumya for active psoriatic arthritis, adding another approved biologic option competing for the same expanding patient pool Cosentyx serves. The filing reflects how multiple manufacturers are seeking to expand their own labels even as biosimilar competition against the Cosentyx molecule itself builds in parallel.

Restraints: Oral small-molecule alternatives are drawing some patients away from injectable biologics earlier in treatment

A meaningful restraint is the growing availability of oral alternatives for milder disease, which lets some patients and prescribers delay or avoid injectable biologic therapy altogether rather than starting on a product like Cosentyx at an earlier disease stage. This shift does not eliminate biologic demand but does push some first-line decisions toward a lower-cost oral option before an injectable is even seriously considered, trimming the pool of newly eligible biologic candidates each year across several major markets at the same time.

A second restraint is the complexity of specialty-pharmacy prior authorization and benefits verification, which can delay how quickly a newly diagnosed patient actually starts therapy regardless of which IL-17 or IL-23 inhibitor a prescriber ultimately selects. This administrative friction affects the entire drug class rather than Cosentyx specifically, but it still slows the pace at which overall demand converts into dispensed prescriptions across nearly every major reimbursement system this market report covers in detail throughout the forecast period.

Opportunities: Geographic expansion through licensing partnerships is opening new commercialization paths for biosimilar developers

The clearest opportunity lies in licensing and commercialization partnerships that let a biosimilar developer reach markets its own regulatory and sales infrastructure could not efficiently cover alone, accelerating how quickly biosimilar competition against Cosentyx can spread once a single approval is secured in a lead market. These partnerships let smaller developers compete credibly against Novartis's established global distribution network well before building out that scale themselves across every market they eventually plan to enter and serve directly.

A second opportunity is emerging in markets where biosimilar competition has not yet arrived, since a developer with multiple approvals already secured elsewhere can use that regulatory track record to accelerate filings in markets still dominated entirely by the originator brand. Developers that move first into these less-contested markets stand to capture durable early share before additional biosimilar competitors eventually follow them in, a sequencing advantage that is difficult for later entrants to fully reverse once it is established in a given market.

⮞In November 2025, Bio-Thera Solutions and Dr. Reddy's Laboratories announced an exclusive licensing and commercialization agreement covering BAT2306, a secukinumab biosimilar, for Southeast Asian markets including Indonesia, Thailand, Vietnam and the Philippines. The partnership lets Bio-Thera reach a set of Southeast Asian markets through Dr. Reddy's existing regional regulatory and commercial infrastructure rather than building that capability independently.

Cosentyx Drug Market Key Players

• Novartis International AG

• Celltrion, Inc.

• CSPC Pharmaceutical Group Limited

• Bio-Thera Solutions, Ltd.

• Taizhou Mabtech Pharma & Biotech Co., Ltd.

• Livzon Pharmaceutical Group Inc.

• Dr. Reddy's Laboratories Ltd.

Cosentyx Drug Market Report Scope: